S'abonner

Distribution of COPD-related symptoms in the Middle East and North Africa: Results of the BREATHE study - 04/01/13

Doi : 10.1016/S0954-6111(12)70012-4 
Mohamed Awad Tageldin a, Salim Nafti b, Javaid Ahmed Khan c, Chakib Nejjari d, Majed Beji e, Bassam Mahboub f, Nathir M. Obeidat g, Esra Uzaslan h, Abdullah Sayiner i, Siraj Wali j, Nauman Rashid k, Abdelkader El Hasnaoui k, A,

on behalf of the BREATHE Study GroupB

  BREATHE Steering Committee members (in alphabetical order of names): Ashraf Alzaabi, Zayed Military Hospital, Abu Dhabi, UAE; Majed Beji, University of Tunis El Manar, Faculty of Medicine of Tunis, La Rabta Hospital, Tunis, Tunisia; Ali Ben Kheder, Abderrahmane Mami Hospital, Tunis, Tunisia; Magdy Idrees, Riyadh Military Hospital, Riyadh, Saudi Arabia; Ghali Iraqui, Moulay Youssef Hospital, Rabat, Morocco; Arshad Javaid, Lady Reading Hospital, Peshawar, Pakistan; Javaid Ahmed Khan, Aga Khan University Hospital, Karachi, Pakistan; Adel Khattab, Ain Shams University, Cairo, Egypt; Marie Louise Koniski, Lebanese American University, Beirut, Lebanon; Bassam Mahboub, University of Sharjah, Sharjah, UAE; Salim Nafti, Mustapha Bacha Hospital, Algiers, Algeria; Nathir M. Obeidat, University of Jordan, Amman, Jordan; Mehmet Polatli, Adnan Menderes University, Aydin, Turkey; Abdullah Sayiner, Ege University, Izmir, Turkey; Naem Shahrour, Alasaad University Hospital, Damascus, Syria; Mohamed Awad Tageldin, Ain Shams University, Cairo, Egypt; Samya Taright, Bab-El-Oued Hospital, Algiers, Algeria; Esra Uzaslan, Uludag University Medical Faculty, Bursa, Turkey; Siraj Wali, King Abdulaziz University, Jeddah, Saudi Arabia.

a Ain Shams University, Cairo, Egypt 
b Mustapha Bacha Hospital, Algiers, Algeria 
c Aga Khan University Hospital, Karachi, Pakistan 
d Faculty of Medicine of Fez, Fez, Morocco 
e University of Tunis El Manar, Faculty of Medicine of Tunis, La Rabta Hospital, Tunis, Tunisia 
f University of Sharjah, Sharjah, UAE 
g University of Jordan, Amman, Jordan 
h Uludag University Medical Faculty, Bursa, Turkey 
i Ege University, Izmir, Turkey 
j King Abdulaziz University, Jeddah, Saudi Arabia 
k GlaxoSmithKline, Dubai, UAE 

* Corresponding author. Dr Abdelkader El Hasnaoui, GlaxoSmithKline, PO Box 50199, Dubai, United Arab Emirates. Tel.: +971 4409 6305; fax: +971 4332 3071

Summary

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. However, its epidemiology in many developing countries is poorly characterised. The objective of this analysis was to evaluate respiratory symptoms which could be COPD-related in a large sample of individuals aged ≥40 years in ten countries in the Middle East and North Africa (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria, Tunisia, Turkey and United Arab Emirates), together with Pakistan, using a standardised methodology. A random sample of 457,258 telephone numbers was contacted. A screening questionnaire was administered to each eligible participant, which included six questions relating to respiratory symptoms. Of 65,154 eligible subjects, 62,086 agreed to participate and 61,551 provided usable data. The age- and gender-adjusted prevalence of symptoms (persistent productive cough or breathlessness or both) was 14.3% [95% CI: 14.0–14.6%], ranging from 7.2% in UAE to 19.1% in Algeria. Symptoms were more frequent (p < 0.0001) in women (16.7%) than in men (12.2%). The adjusted prevalence of COPD according to the “epidemiological” definition (symptoms or diagnosis and cigarette use ≥10 pack·years) was 3.6% [95% CI: 3.5–3.7%] (range: 1.9% in UAE to 6.1% in Syria). COPD was more frequent (p < 0.0001) in men (5.2%) than in women (1.8%). The frequency of symptoms was significantly higher in cigarette smokers (p< 0.001), as well as in waterpipe users (p < 0.026). In conclusion, the prevalence of COPD in this region seems to be lower than that reported in industrialised countries. Under-reporting and risk factors other than smoking may contribute to this difference.

Le texte complet de cet article est disponible en PDF.

Keywords : COPD, Symptoms, Middle East, North Africa, BREATHE study, Prevalence, Chronic bronchitis, Smoking


Plan


 BREATHE core team members: Abdelkader El Hasnaoui, GlaxoSmithKline, Dubai, UAE; Nauman Rashid, GlaxoSmithKline, Dubai, UAE; Aïcha Lahlou, MS Health, Rabat, Morocco; Adam Doble, Foxymed, Paris, France, Hocine Salhi, Foxymed, Paris, France and Chakib Nejjari Faculty of Medicine of Fez, Fez, Morocco.
Conflict of interest statement
MAT, SN, JAK, MB, BM, NMO, EU, AS and SW have received honoraria from GlaxoSmithKline Laboratories for their contribution to the BREATHE study. CN advised on the data management and statistical analysis of the results of the BREATHE study on behalf of GlaxoSmithKline Laboratories. NR and AEH are employees of GlaxoSmithKline Laboratories, which funded the BREATHE study and market a number of treatments for COPD.


© 2012  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 106 - N° S2

P. S25-S32 - décembre 2012 Retour au numéro
Article précédent Article précédent
  • Smoking habits in the Middle East and North Africa: Results of the BREATHE study
  • Adel Khattab, Arshad Javaid, Ghali Iraqi, Ashraf Alzaabi, Ali Ben Kheder, Marie-Louise Koniski, Naem Shahrour, Samya Taright, Magdy Idrees, Mehmet Polatli, Nauman Rashid, Abdelkader El Hasnaoui, on behalf of the BREATHE Study Group B
| Article suivant Article suivant
  • Management of chronic obstructive pulmonary disease in the Middle East and North Africa: Results of the BREATHE study
  • Majdy Idrees, Marie-Louise Koniski, Samya Taright, Naeem Shahrour, Mehmet Polatli, Ali Ben Kheder, Ashraf Alzaabi, Ghali Iraqi, Adel Khattab, Arshad Javed, Nauman Rashid, Abdelkader El Hasnaoui, on behalf of the BREATHE Study Group B

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.